Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2026
Tumour necrosis factor-α inhibitors, immune-mediated inflammatory diseases, and bloodstream infections: results from a nationwide case-control study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Leding Cæcilie, Meddis Alessandra, Holler Jon Gitz, Burisch Johan, Kragstrup Tue Wenzel, Skov Lone, Benfield Thomas
Аннотация
OBJECTIVES: Severe infection risk associated with tumour necrosis factor-α inhibitors (TNFis) remains a concern. We aimed to assess the association between TNFi and bloodstream infections (BSIs) in a population-based setting.
METHODS: Nationwide, registry-based case-control study including all adults from 2010 to 2024 with a first-time microbiologically confirmed BSI (cases) compared with age and sex-matched controls from the general population. Users were defined as individuals with TNFi exposure within 6 months prior to the date of BSIs. Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were estimated using conditional logistic regression. We further assessed risk variation by type of TNFi, pathogen, and underlying disease.
RESULTS: We included 174,137 cases and 1 741 294 controls. Users had significantly increased odds of BSIs compared with nonusers (aOR, 1.41; 95% CI, 1.30-1.52), driven by increased odds among users of adalimumab and infliximab (aOR, 1.51; 95% CI, 1.33-1.72, and aOR, 2.01; 95% CI, 1.76-2.29). The use of certolizumab pegol and etanercept was associated with lower odds of BSIs, and golimumab with higher odds compared with nonuse, although not statistically significant. Species-specific analyses showed increased odds of BSIs with Escherichia coli (aOR, 1.33; 95% CI, 1.16-1.53), Staphylococcus aureus (aOR, 1.69; 95% CI, 1.40-2.06), Streptococcus pneumoniae (aOR, 1.46; 95% CI, 1.05-2.04), and Enterococcus faecium (aOR, 1.62; 95% CI, 1.04-2.53). Highest odds were observed in individuals with inflammatory bowel disease (aOR, 2.27; 95% CI, 1.93-2.66), followed by individuals with rheumatoid arthritis. Compared with TNFi monotherapy, concomitant glucocorticoids increased the odds (aOR, 2.63; 95% CI, 2.06-3.36).
CONCLUSIONS: TNFi use is associated with increased odds of BSIs and was observed across the most frequent species. Odds varied by TNFi type and underlying disease, with the highest odds among patients with inflammatory bowel disease, emphasizing the need for individualized infection risk assessment.
METHODS: Nationwide, registry-based case-control study including all adults from 2010 to 2024 with a first-time microbiologically confirmed BSI (cases) compared with age and sex-matched controls from the general population. Users were defined as individuals with TNFi exposure within 6 months prior to the date of BSIs. Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were estimated using conditional logistic regression. We further assessed risk variation by type of TNFi, pathogen, and underlying disease.
RESULTS: We included 174,137 cases and 1 741 294 controls. Users had significantly increased odds of BSIs compared with nonusers (aOR, 1.41; 95% CI, 1.30-1.52), driven by increased odds among users of adalimumab and infliximab (aOR, 1.51; 95% CI, 1.33-1.72, and aOR, 2.01; 95% CI, 1.76-2.29). The use of certolizumab pegol and etanercept was associated with lower odds of BSIs, and golimumab with higher odds compared with nonuse, although not statistically significant. Species-specific analyses showed increased odds of BSIs with Escherichia coli (aOR, 1.33; 95% CI, 1.16-1.53), Staphylococcus aureus (aOR, 1.69; 95% CI, 1.40-2.06), Streptococcus pneumoniae (aOR, 1.46; 95% CI, 1.05-2.04), and Enterococcus faecium (aOR, 1.62; 95% CI, 1.04-2.53). Highest odds were observed in individuals with inflammatory bowel disease (aOR, 2.27; 95% CI, 1.93-2.66), followed by individuals with rheumatoid arthritis. Compared with TNFi monotherapy, concomitant glucocorticoids increased the odds (aOR, 2.63; 95% CI, 2.06-3.36).
CONCLUSIONS: TNFi use is associated with increased odds of BSIs and was observed across the most frequent species. Odds varied by TNFi type and underlying disease, with the highest odds among patients with inflammatory bowel disease, emphasizing the need for individualized infection risk assessment.